Peetz Christopher 4

What Happened

• Christopher Peetz, CEO of Mirum Pharmaceuticals (MIRM), exercised stock options and sold shares on July 6, 2026. He exercised 20,000 options at $2.94 each (cost $58,720) and the filing reports a separate derivative disposition of 20,000 shares at $0.00 (the filing does not explain the zero value). On the same date he sold 20,000 shares in four open-market transactions for aggregate proceeds of $2,445,383.

Key Details

• Transaction date: July 6, 2026; Form 4 filed July 8, 2026 (timely)
• Sales breakdown (open market):
  • 12,134 shares @ $121.65 = $1,476,101 (wtd avg; range $121.11–$122.105)
  • 4,181 shares @ $122.34 = $511,504 (wtd avg; range $122.13–$123.1125)
  • 1,975 shares @ $123.74 = $244,387 (wtd avg; range $123.24–$124.10)
  • 1,710 shares @ $124.79 = $213,391 (wtd avg; range $124.27–$124.94)
  • Total sold: 20,000 shares for $2,445,383
• Option exercise: 20,000 shares acquired at $2.94 each for $58,720; option fully vested (footnote F6)
• Additional derivative entry: 20,000 shares reported disposed at $0.00 (filing gives no further detail)
• Sales were made pursuant to a Rule 10b5-1 trading plan adopted March 2, 2026 (footnote F1)
• Shares owned after the transactions: not specified in the provided filing excerpt

Context

• The filing shows an exercise of options and contemporaneous sales totaling the same number of shares (20,000 acquired vs. 20,000 sold). This pattern is common when executives exercise options and sell shares under a prearranged plan; the Form 4 does not state the settlement mechanics.
• Sales under a 10b5-1 plan are typically pre-scheduled and generally viewed as routine rather than an ad hoc signal of sentiment; purchases (which can be a stronger bullish signal) were limited to the option exercise here.